Study Indicates Cyclin D1b Protein Could Be Biomarker for Prostate Cancer Metastasis
A study carried out by researchers at the Thomas Jefferson University of Philadelphia has indicated that elevated levels of the variant cell cycle regulator known as cyclin D1b could very well be a biomarker for metastasis prostate cancer. The findings of this study have been published in the Journal of Clinical Investigation.
Delicia Honen Yard of OncologyNurse Advisor published an article January 18, 2013 providing more insights on how this protein. Extracts from the online post reveals that you will find useful include:
As a highly oncogenic variant of the cell cycle regulator cyclin D1 (cyclin D1a), cyclin D1b is known to harbor divergent and highly oncogenic functions in cancer. Although this protein is induced during disease progression in many types of cancer, the mechanisms underlying its function remain poorly understood, explained Karen E. Knudsen, PhD, and colleagues in The Journal of Clinical Investigation (2013;123:493–508).
Knudsen is the Hilary Koprowski Chair of the Departments of Cancer Biology, Urology, and Radiation Oncology at Thomas Jefferson University in Philadelphia, Pennsylvania, and Deputy Director for Basic Science at Jefferson’s Kimmel Cancer Center.
Knudsen’s investigative team found that cyclin D1b, but not cyclin D1a, regulates a large gene network. The network was shown to cooperate with androgen receptor (AR) signaling to drive metastatic progression in multiple models of prostate cancer.
The researchers also discovered that cyclin D1b expression can directly promote AR-dependent expression of the pro-metastatic gene SNA12 (Slug). This action dramatically increased metastatic events to soft tissues in animal models, affirmed Knudsen in a statement issued by Thomas Jefferson University.
“Our data describe how cross-talk between the cell cycle and AR can rewire the AR signaling axis to enhance the expression of genes [that] elicit metastasis in both early and castration-resistant prostate cancer models,” noted Knudsen in the statement. “Identification of AR-driven pathways [that] mediate metastatic progression represents a significant leap forward in our attempts to effectively manage prostate cancer progression.”
Conclusively, for more details on the findings of this research, you should checkout the full report as published in the Journal of Clinical Investigation volume 123, Issue 1 of(January 2, 2013).
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- Protein SPDEF in Prostate Cancer Cells Don’t Survive Possible Metastasis Sites
- Protein Compositions in Gene Alterations Could Lead To New Discoveries in Drugs And Diagnostic Methods For Prostate Cancer
- Prostrate Cancer Metastasis – Scalp Metastasis of Prostate Cancer
- Researchers Discover Protein In Prostate Cancer Cells that Could Help to Determine The Most Suitable Treatment
- Metastasis Prostate Cancer
- Bone Metastasis Prostate Cancer – Symptoms And Treatments
- EZH2 Protein Increases Hormone Resistant Prostate Cancer and Opens up New Way for Treating Prostate Cancer
- Metastasis Prostate Cancer
- Advanced Prostate Cancer and Bone Metastasis
- Prostate Cancer Spreading – Growth Progression and Metastasis
- Bone Metastasis Prostate Cancer – Why You Should Be Worried
- Stage IV Prostate Cancer – Bone Metastasis Treatment and Prognosis
- Prostate Cancer Metastasis Organs and Bones Affected and Treatment
- Advanced Prostate Cancer Bone Metastasis Prognosis
- Prostate Cancer D Bone Metastasis Treatment